What's Next for Advanced Melanoma?

Video

Jason Luke, MD, assistant professor at the University of Chicago Medicine, discusses what he hopes the future of advanced melanoma treatment will look like.

Jason Luke, MD, assistant professor at the University of Chicago Medicine, discusses what he hopes the future of advanced melanoma treatment will look like.

With new agents and combinations, long-term melanoma survival will continue to improve. Luke hopes that the future landscape for advanced melanoma -- and all cancers -- will become similar to managing a chronic disease. To do this, there must be treatments with high efficacy and low toxicity profiles.

Recent Videos
image of a woman in front of a blue background with a navy top
woman with a white top sitting in front of a green wall
a man wearing a suit and tie in front of a green screen with the ONN logo
Related Content
dark blue background with a white outline indicating layers of skin

Cemiplimab as Adjuvant Therapy Improves DFS in High-Risk Cutaneous Squamous Cell Carcinoma

Caroline Seymour
January 20th 2025
Article

Adjuvant cemiplimab demonstrated a statistically significant improvement in DFS compared to placebo in post-surgical patients with high-risk CSCC, impacting post-operative care considerations.

The Vitals Podcast

Amber Pierce Underscores the Importance of 2-Step Verification With Relatlimab/Nivolumab

Lindsay Fischer
May 19th 2023
Podcast

Amber Pierce RN, BSN, OCN, highlights the importance of a 2-step verification process with fixed-dose regimen therapies.

FDA on clipboard

Accelerated Approval Sought for RP1-Nivolumab Combo for Pretreated Melanoma

Ashling Wahner
November 24th 2024
Article

The FDA received a biologics license application for accelerated approval of RP1 plus nivolumab for advanced, pretreated melanoma.

the vitals

Krista Rubin Breaks Down Best Practices With Tebentafusp for Uveal Melanoma

Lindsay Fischer
May 4th 2023
Podcast

Krista M. Rubin, RN, MS, FNP-BC, highlights how nurses can help patients with uveal melanoma anticipate and manage adverse events during the step-up dosing period with tebentafusp.

melanoma/skin

10-Year Data Support Pembrolizumab as Standard for Advanced Melanoma

Kristi Rosa
Published: September 21st 2024 | Updated: September 21st 2024
Article

Pembrolizumab led to improved survival over ipilimumab in patients with unresectable advanced melanoma, according to long-term data.

Two Phase 3 Trials of Pembrolizumab in NSCLC, CSCC to Be Discontinued By Merck

Two Phase 3 Trials of Pembrolizumab in NSCLC, CSCC to Be Discontinued By Merck

Kyle Doherty
September 8th 2024
Article

Merck has discontinued the KEYNOTE-867 and KEYNOTE-630 trials evaluating pembrolizumab in non-small cell lung cancer and cutaneous squamous cell carcinoma.